Privately-held Swiss firm Ferring Pharmaceuticals and Foresee Pharmaceuticals (TWO: 6576) have entered into an exclusive worldwide development and option agreement.
Ferring says the aim is to leverage the Taiwan-based firm’s proprietary and unique stabilized injectable formulation platform (SIF) for the development of long duration, controlled release formulations of a peptide therapeutic.
Under the terms of the agreement, Ferring will fund the development work and, on completion, will have the right to exercise its option and enter into a definitive agreement with Foresee. Execution of a definitive agreement would entitle Foresee to additional payments including upfront, milestones and royalties based on net sales of the product(s) commercialized by Ferring.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze